Update on the Incidence of Paediatric Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease, Aquaporin‐4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder, and Other Acquired Demyelinating Syndromes in the Netherlands, 2017–2025, Including the COVID ‐19 Pandemic
European Journal of Neurology · 2026
DOI: 10.1111/ene.70723 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Sandy Molenaar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Erasmus University Medical Centre, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Multiple Sclerosis, Aquaporin 4, COVID-19. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stichting MS Research, Postcodeloterij.
Abstract (Originalsprache)
Background
Acquired demyelinating syndromes (ADS) in children include multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD), and other seronegative disorders. We previously reported an increased incidence of overall paediatric ADS and MS between 2007 to 2010 and 2011–2016 (from 0.66 to 0.80 and 0.15 to 0.26 per 100,000 person‐years, respectively). Environmental factors, including viral exposure, may influence these rates. Comparing a recent period that includes the COVID‐19 pandemic provides an opportunity to study temporal patterns.
Methods
Children < 18 years with a first demyelinating event between January 2017 and June 2025 were prospectively included in the nationwide PROUDkids 2.0 study or referred to the Dutch Paediatric MS Centre. Diagnoses followed international criteria, and incidence rates were calculated using national population data.
Results
Among 257 included children, 111 (43%) had MS, 93 (36%) MOGAD, 5 (2%) AQP4+ NMOSD, and 48 (19%) seronegative ADS. Overall ADS incidence was 0.91 per 100,000 person‐years, with MS 0.40, MOGAD 0.33, AQP4+ NMOSD 0.02, and seronegative ADS 0.16 per 100,000 person‐years. Compared with 2011–2016 (0.26 per 100,000), MS incidence increased, whereas other ADS rates remained stable. MS incidence declined after COVID‐19 restrictions, particularly among adolescents, while MOGAD incidence rose modestly in younger children during the COVID restrictions.
Conclusions
Paediatric MS incidence continues to rise in the Netherlands, whereas the incidence of other ADS remains stable. Temporal variations in the incidence of MS and MOGAD during and after the COVID‐19 pandemic may reflect the influence of viral exposure in their pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Erasmus University Medical Centre, Rotterdam, the Netherlands.
- MS Center ErasMS, Erasmus University Medical Centre, Rotterdam, the Netherlands.
ORCID-Profile: Sandy Molenaar, Michiel S J Buijze, Arlette L Bruijstens, Yu Yi M Wong, Beatrijs H A Wokke, Rinze F Neuteboom
Förderung
- Stichting MS Research
- Postcodeloterij
Zitieren
APA
Molenaar, S., Buijze, M. S. J., Bruijstens, A. L., Wong, Y. Y. M., Quist, M. A., de Mol, C. L., Wokke, B. H. A., Neuteboom, R. F., & Dutch Study Group for Paediatric Multiple Sclerosis and Acute Disseminated Encephalomyelitis (2026). Update on the Incidence of Paediatric Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease, Aquaporin‐4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder, and Other Acquired Demyelinating Syndromes in the Netherlands, 2017–2025, Including the COVID ‐19 Pandemic. European Journal of Neurology. https://doi.org/10.1111/ene.70723
Vancouver
Molenaar S, Buijze MSJ, Bruijstens AL, Wong YYM, Quist MA, de Mol CL, et al. Update on the Incidence of Paediatric Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease, Aquaporin‐4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder, and Other Acquired Demyelinating Syndromes in the Netherlands, 2017–2025, Including the COVID ‐19 Pandemic. European Journal of Neurology. 2026. doi:10.1111/ene.70723
BibTeX
@article{Molenaar2026,
author = {Molenaar, Sandy and Buijze, Michiel S J and Bruijstens, Arlette L and Wong, Yu Yi M and Quist, Maud A and de Mol, C Louk and Wokke, Beatrijs H A and Neuteboom, Rinze F and Dutch Study Group for Paediatric Multiple Sclerosis and Acute Disseminated Encephalomyelitis, Dutch Study Group for Paediatric Multiple Sclerosis and Acute Disseminated Encephalomyelitis},
title = {Update on the Incidence of Paediatric Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease, Aquaporin‐4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder, and Other Acquired Demyelinating Syndromes in the Netherlands, 2017–2025, Including the COVID ‐19 Pandemic},
journal = {European Journal of Neurology},
year = {2026},
doi = {10.1111/ene.70723}
}
EUVIMED